Sign in

You're signed outSign in or to get full access.

Michael Torok

Director at AMARIN CORP PLC\UKAMARIN CORP PLC\UK
Board

About Michael Torok

Michael Torok, age 46, was appointed as a non-executive, independent director of Amarin on April 4, 2025. He co-founded and serves as Managing Director of JEC Capital Partners, with prior roles as CFO of Integrated Dynamics Engineering and earlier positions at PwC. He holds a B.S. in Accounting & Finance and a Master’s in Finance from Boston College. He is nominated for re‑election at the May 13, 2025 AGM and, as of the proxy date, is considered independent by the Board .

Past Roles

OrganizationRoleTenureCommittees/Impact
JEC Capital Partners, LLCCo‑Founder & Managing Director2008–presentCapital allocation, M&A and operational improvement focus as investor/operator .
Integrated Dynamics Engineering (acq. by Aalberts)Chief Financial Officer2006–2009Led finance through sale to Aalberts Industries (XAMS: AALB) .
PricewaterhouseCoopers LLPVarious rolesEarly careerFinancial services focus .

External Roles

OrganizationRoleTenureNotes
Liberated Syndication, Inc. (Libsyn)DirectorDec 2022–presentPublic company board experience .
Carisma Therapeutics Inc. (NASDAQ: CARM)DirectorMar 2023–Oct 2024Former public company directorship .
Photon Control Inc. (TSX: PHO)Director2016–2018Former public company directorship .
Symbility Solutions Inc.Director2015–2018Former public company directorship .
Various (general)Committee contributionsN/APress release notes contributions across audit, compensation, nominating & governance, strategic and pricing committees at past boards .

Board Governance

  • Independence: The Board determined all directors other than the CEO are independent; this includes Mr. Torok as of the April 10, 2025 proxy .
  • Committee assignments: On appointment (Apr 4, 2025) he had not been assigned to any committees; committee assignments may be set after the AGM .
  • Attendance: The Board held 10 meetings in 2024 and all then‑serving directors met the 75% attendance threshold; Torok was appointed in 2025, so no 2024 attendance record applies to him .
  • Board leadership: Independent Chair (Dr. Odysseas Kostas); key committees are fully independent; independent directors hold sessions at every meeting .
  • Re‑election: Ordinary resolution to re‑elect Michael Torok at the 2025 AGM (Proposal No. 13) .

Fixed Compensation (Director)

ComponentAmount/TermsNotes
Annual Board Retainer (non‑employee director)$62,500Paid quarterly in arrears; proration for partial year .
Non‑Executive Chairman Retainer$95,000Not applicable to Torok unless designated Chair .
Committee Member RetainersAudit: $12,000; Remuneration: $10,000; Nominating & Gov: $5,000In addition to Board retainer; Torok had no assignments at appointment .
Committee Chair RetainersAudit: $25,000; Remuneration: $20,000; Nominating & Gov: $11,000In addition to Board retainer .
Retainer settlement electionCash or unregistered ordinary shares (ADS‑priced or par floor), election window each quarterProvides alignment option; priced at greater of ADS close +10 days or £0.50 par value .

Performance Compensation (Director Equity)

Equity ElementGrant Value/MixVestingOther Terms
Initial grant for new directors (as revised Feb 2024)$262,500 total; 75% options / 25% RSUsOptions: 1/3 at yr 1 then quarterly over next 2 yrs; RSUs: annual over 3 yrsUnder 2020 Plan; CIC: director equity fully vests on change of control .
Ongoing annual grant$175,000 total; 75% options / 25% RSUsOptions: annual over 3 yrs; RSUs: annual over 3 yrsUnder 2020 Plan; CIC: director equity fully vests on change of control .

Structure signals pay‑for‑performance: heavier option weighting (75%) shifts director equity toward stock price outcomes; Amarin reduced director equity sizes and increased option mix in 2023/Jan 2024 to align with market medians .

Other Directorships & Interlocks

CompanySectorRolePotential Interlock/Conflict Relevance
Liberated Syndication, Inc.Podcasting/AdtechDirectorNo disclosed commercial ties to Amarin; governance only .
Carisma Therapeutics Inc.BiotechFormer DirectorNo disclosed ties to Amarin; tenure ended Oct 2024 .
Photon Control Inc.Semi equipmentFormer DirectorNo disclosed ties to Amarin .
Symbility Solutions Inc.InsurtechFormer DirectorNo disclosed ties to Amarin .

The Company reports no related‑party transactions since Jan 1, 2024, and Torok is not party to any Item 404(a) transactions on appointment .

Expertise & Qualifications

  • Capital markets, M&A, capital resources, and operational improvements experience (JEC, CFO background) .
  • Financial oversight and board experience; contribution across core board committees noted in press release .
  • Accounting and finance academic credentials (Boston College) .

Equity Ownership

Holder (direct/indirect)SharesNotes
Michael Torok – direct970,000Directly owned as of Apr 4, 2025 .
JEC II Associates, LLC (managed by Torok)3,000,000Indirect beneficial ownership via manager status .
The MOS Trust (trustee manager entity managed by Torok)880,000Indirect beneficial ownership via trustee manager role .
Total beneficial ownership4,850,000Represents 1.17% of outstanding shares (414,186,296) .
  • Ownership guidelines (directors): 3× annual cash retainer; five years to attain (non‑employee directors elected in 2023 have until 2028) .
  • Hedging/pledging: Prohibited absent Audit Committee approval; Company anti‑hedging/anti‑pledging policy applies to directors .

Governance Assessment

  • Alignment: Material personal/affiliated ownership of ~1.17% aligns incentives with shareholders; option‑heavy director equity mix further ties compensation to share price outcomes .
  • Independence and oversight: Board deems him independent; independent Chair and fully independent key committees support effective oversight, though Torok had no committee assignment at appointment, limiting near‑term committee‑level influence until assignments are made post‑AGM .
  • Engagement/attendance: Board met 10 times in 2024 with all then‑directors meeting attendance thresholds; Torok’s attendance will be assessable in 2025 reporting .
  • Pay structure quality: Director pay offers cash/equity election and market‑median sizing; change‑in‑control full vesting is standard but can be shareholder‑sensitive; the increased option weighting is a positive alignment signal .
  • Conflicts and related‑party risk: Company discloses no related‑party transactions; 8‑K affirms no Item 404(a) transactions for Torok on appointment; hedging/pledging restrictions mitigate alignment risks. Continued monitoring warranted given indirect holdings via entities he manages, although no pledges are disclosed .

RED FLAGS (monitor)

  • No committee assignment at appointment (may be temporary; monitor post‑AGM committee placements) .
  • Change‑in‑control acceleration for director equity (industry standard but can face investor scrutiny) .

Supportive Signals

  • Significant beneficial ownership and option‑heavy director equity structure .
  • Independent status within an independently led board framework .
  • No related‑party transactions disclosed; deed of indemnity to be executed in standard form .

Employment & Contracts (Director)

  • Appointment date: April 4, 2025; service through 2025 AGM; nominated for re‑election .
  • Deed of indemnity: Company expects to enter into standard director deed of indemnity with Torok .

Director Compensation Structure Analysis

Aspect2024–2025 Policy DetailImplication
Cash retainer$62.5k + committee/Chair fees; quarterly; share election availableFlexibility and potential for higher equity alignment via share elections .
Initial equity award$262.5k (75% options/25% RSUs); staggered vestingStrong price alignment; vesting supports retention .
Annual equity award$175k (75% options/25% RSUs)Sustained price alignment over tenure .
CIC treatmentFull vesting of director awardsStandard; monitor investor sentiment on CIC acceleration .

Say‑on‑Pay & Shareholder Feedback (context)

  • 2024 say‑on‑pay approval ~79.5% of votes cast; Board and Remuneration Committee expanded engagement and simplified incentive design, including heavier option weighting and clearer outcomes‑based goals (executive program context) .

Related‑Party Transactions

  • None reported since Jan 1, 2024; Torok specifically not party to any Item 404(a) transactions per his 8‑K appointment disclosure .

Past Roles (detail table)

OrganizationRoleTenureCommittees/Impact
JEC Capital Partners, LLCCo‑Founder & Managing Director2008–presentInvestor/operator; capital markets, M&A, operations .
Integrated Dynamics Engineering (Aalberts Industries)CFO2006–2009Led finance; sale to Aalberts .
PwCVariousN/AFinancial services focus .

External Roles (detail table)

CompanyRoleTenureNotes
Liberated Syndication, Inc.DirectorDec 2022–presentPublic company board .
Carisma Therapeutics Inc.DirectorMar 2023–Oct 2024Former director .
Photon Control Inc.Director2016–2018Former director .
Symbility Solutions Inc.Director2015–2018Former director .
Various (general)Committee contributionsN/AContributions across audit/comp/N&G/strategic/pricing committees (press release) .

Equity Ownership (detail table)

CategoryShares% of OutstandingSource/Notes
Direct970,000As of April 4, 2025 .
Indirect – JEC II Associates, LLC (manager: Torok)3,000,000Indirect via entity managed by Torok .
Indirect – The MOS Trust (trustee manager entity managed by Torok)880,000Indirect via trust arrangement .
Total4,850,0001.17% (of 414,186,296)Beneficial ownership table and footnote; outstanding share count as of Feb 28, 2025 .

Notes on Policies Relevant to Alignment

  • Director stock ownership guideline: 3× annual cash retainer; 5 years to comply (directors from 2023 cohort have until 2028) .
  • Insider trading policy: Prohibits hedging and pledging absent Audit Committee approval; clawback policy in place for executives (governance backdrop) .